Fig. 4From: Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agentsChanges from baseline in NYHA classification at week 24 in the subgroups stratified by the baseline use of glucose-lowering agents. All p values were for the comparisons between the treatment groups. DPP-4 dipeptidyl peptidase-4, NYHA New York Heart AssociationBack to article page